Compare Arko Corp. (ARKO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs Quest Diagnostics Inc — how do they compare? Arko Corp. trades at $4.51 (market cap $499.23M), while Quest Diagnostics Inc trades at $237.09 (market cap $26.24B). The key difference: Quest Diagnostics Inc is far larger — about 52.6× Arko Corp.'s market cap, and Arko Corp. pays the higher dividend (2.7%). Which is the better fit depends on your goals.
| ARKO | DGX | |
|---|---|---|
Market Cap | $499.23M | $26.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $238.50 |
52-Week Low | $3.82 | $173.49 |
Enterprise Value | $2.68B | $32.00B |
Dividend Yield | 2.7% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.46, down 5.11% on the day, reflecting bearish technical signals and recent earnings miss. The company maintains a low P/S ratio of 0.06 and pays consistent dividends, but faces declining revenue and thin net margins. Recent news highlights weak Q2 2026 results and softer retail demand, with analysts holding a neutral stance.
Outlook remains cautious due to earnings volatility and competitive pressures, though the dividend yield and low valuation offer some value. Key risks include consumer spending sensitivity and high debt levels, requiring close monitoring of margin defense strategies and fuel pricing discipline for recovery.
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
